You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: February 22, 2024

CLINICAL TRIALS PROFILE FOR DEXYCU KIT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Dexycu Kit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02006888 ↗ The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery Completed ICON Bioscience Inc Phase 3 2014-01-01 The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.
NCT02547623 ↗ Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery Completed ICON Bioscience Inc Phase 3 2015-11-06 The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion criteria will be randomized to 1 of 2 treatment groups - A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone, equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or; - Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times daily (QID) for 3 weeks Safety will be assessed by adverse events (AEs), slit lamp biomicroscopy, fundus examination, intraocular pressure (IOP), visual acuity, and specular microscopy endothelial cell count.
NCT04184999 ↗ Effect of Intraoperative Dexamethasone on Post-op Dry Eye Completed SR Cornea Consultants Phase 4 2019-08-10 To compare the signs and symptoms of dry eye after cataract surgery between subjects randomized to receive intraoperative dexamethasone in addition to the use of a standard topical post-op treatment regimen.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexycu Kit

Condition Name

Condition Name for Dexycu Kit
Intervention Trials
Cataract 6
Cataract Surgery 1
Cataracts 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexycu Kit
Intervention Trials
Cataract 8
Inflammation 4
Neoplasms, Plasma Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexycu Kit

Trials by Country

Trials by Country for Dexycu Kit
Location Trials
United States 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexycu Kit
Location Trials
California 4
Florida 2
South Carolina 2
New York 2
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexycu Kit

Clinical Trial Phase

Clinical Trial Phase for Dexycu Kit
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexycu Kit
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 3
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexycu Kit

Sponsor Name

Sponsor Name for Dexycu Kit
Sponsor Trials
EyePoint Pharmaceuticals, Inc. 4
ICON Bioscience Inc 2
SR Cornea Consultants 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexycu Kit
Sponsor Trials
Industry 9
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Express Scripts
Merck
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.